AMGEN INC Q3 FY2026 earnings call

• Commercial Execution: Product sales grew 8% YoY to $10.4 billion. Six key growth drivers grew 27% YoY, representing over 70% of product sales. Seventeen products annualized at more than $1 billion.
• R&D Milestones: Reported positive Phase III results for Imdeltra (small cell lung cancer), Tespire (eosinophilic esophagitis), and Dezodolibap (Sjogren's disease). These represent first-in-class or best-in-class opportunities.
• Pipeline Advancement: Maritide (obesity/diabetes) completed enrollment in sleep apnea and cardiovascular outcome studies, initiating Type 2 diabetes trials. Dexdilumab advanced to Phase III for discoid lupus based on positive Phase II data.
• Manufacturing & Capital Allocation: Free cash flow was $3.7 billion. Capital expenditures were $600 million, with full-year 2026 CapEx expected at ~$2.6 billion to support manufacturing scale-up, particularly for Maritide.
• Innovation Integration: Leveraging AI and data-driven insights to improve drug discovery, development, and manufacturing efficiency across the organization.

• General Medicine: Total sales grew 8% YoY. Key products include Repatha ($1.1 billion, +37% YoY), Avenity ($751 million, +39% YoY), and Tespire ($538 million, +43% YoY). Together, these three drivers contributed significantly to the segment's growth, with Repatha and Avenity showing strong acceleration in new-to-brand prescriptions.
• Inflammation: Represented by Tespire (also listed under General Medicine above for clarity, but distinct therapeutic area), sales were $538 million (+43% YoY). The segment benefits from deepening adoption among allergists and pulmonologists and expanding into eosinophilic esophagitis.
• Rare Disease: Portfolio grew 21% YoY to $1.6 billion. Uplisna sales surged 191% YoY to $451 million, driven by generalized myasthenia gravis expansion. Tepza generated $526 million (-6% YoY due to prior year inventory buildup).
• Biosimilars: Generated $977 million in sales (+26% YoY). Pablu (biosimilar to Stelara) increased sales 41% YoY to $300 million.
• Innovative Oncology: Portfolio grew 21% YoY to $2.1 billion. Imdeltra sales more than doubled YoY to $406 million. Bonsaito sales increased 27% YoY to $496 million.

• Revenue: Raised 2026 total revenue guidance to $38.9–$39.7 billion.
• EPS: Raised 2026 non-GAAP earnings per share guidance to $22.90–$23.70.
• Operating Margin: Maintained expectation of roughly 45–46% non-GAAP operating margin as a percentage of product sales for full year 2026.
• Other Income/Expense: Anticipated expense of $2.0–$2.1 billion for 2026.
• Tax Rate: Expected non-GAAP tax rate between 15% and 16.5%.
• Share Repurchases: Expectations that buybacks will not exceed $3 billion.
• 2027 Outlook: No anticipated step-down in operating margin compared to 2026 guidance; focus remains on efficient resource allocation and disciplined expense management.

• Clinical Development Risk: Dependence on successful outcomes for late-stage pipeline programs such as Maritide, Dezodolibap, and Xaloridomic. Regulatory approval timelines remain uncertain.
• Competitive Landscape: Intense competition in biosimilars (Updivo, Keytruda BLAs filed) and obesity/diabetes markets (Maritide vs. existing GLP-1s). Need to maintain market share against rapidly evolving competitors.
• Operational Complexity: Managing monitoring requirements and safety profiles (e.g., CRS/ICANS for T-cell engagers like Imdeltra) in community settings outside specialized centers.
• Market Access Challenges: Potential difficulties in securing reimbursement in ex-US markets for Maritide due to consumer-driven dynamics and payer receptivity.
• Inventory Management: Impact of inventory fluctuations on quarter-over-quarter sales comparisons, as seen with Tepza.

Q: Jay Bradner discussed positive Phase III results in systemic Sjogren’s but noted it is difficult to predict outcomes for the symptomatic study (OASIS-303) due to different patient populations. He emphasized waiting for Q4 data readout before commenting further on regulatory strategy. / A: Bradner highlighted that while systemic results were encouraging, the symptomatic trial addresses a distinct population. He stated that Amgen would await the completion of the second Phase III study later this year to provide clearer guidance on the regulatory path and efficacy expectations for symptomatic patients.

Q: Terrence Flynn asked if Amgen would ramp down biosimilar production to free up capacity for the Maritide launch and if blinded tolerability data for Maritide was available. / A: CEO Bob Bradway confirmed that Amgen feels confident in its ability to continue supplying high-quality biosimilars and has no plans to reduce that business to accommodate Maritide capacity needs. CSO Jay Bradner added that they adhere strictly to good clinical practices and will share tolerability data only when the Phase III studies formally read out, maintaining protocol integrity.

Q: Chris Schott asked about the commercial ramp potential for Imdeltra following the transformative Delphi 305 data, specifically regarding reduced monitoring requirements. / A: EVP Murdo Gordon explained that FDA-approved monitoring has already been reduced from 22-24 hours to 6-8 hours for second-line use, facilitating community clinic administration. For the first-line maintenance setting (Delphi 305), monitoring drops to 1-2 hours, which he expects will drive rapid adoption. He noted that oncologists are enthusiastic about the profound survival benefit and improved safety profile in earlier disease settings.

Q: Umar Raffat asked if it is realistic to assume 20,000+ US patients on Tarlatamab (Imdeltra) and if the first-line maintenance opportunity alone could exceed $5 billion. / A: Murdo Gordon declined to provide product-specific guidance but emphasized the large addressable population in first-line maintenance (~35,000 patients in the US) compared to limited second-line numbers. He predicted rapid adoption and long treatment duration due to the medicine's durability. Jay Bradner added that mature data from Delphi 303 showed a median overall survival of 37.9 months, underscoring the unprecedented nature of the benefit.

Q: Alex Hammond asked how Amgen plans to manage T-cell engager risks (CRS) in urology/community settings for prostate cancer (Xaloridomic) and the importance of not requiring a biomarker. / A: Jay Bradner noted that reduced monitoring and fully outpatient cohorts help mitigate risks, and high STEEP1 expression allows treatment without confirmatory biomarkers, simplifying access. Murdo Gordon highlighted the established 'Bispecific Operations Team' used successfully for Imdeltra, which supports community sites with operational guidance, patient education, and advocacy partnerships to ensure safe adoption in GU oncology.